10-Q – 2025-11-04 – cort-20250930.htm

(1) In July 2025, we issued 63,175 shares of common stock as part of a net-share settlement of a cashless option exercise, of which 30,862 shares were surrendered to us in satisfaction of related exercise cost and tax obligations. In August 2025, we issued 206,422 shares of common stock as part of a net-share settlement of a cashless option exercise, of which 91,018 shares were surrendered to us. In September 2025, we issued 31,083 shares of common stock as part of a net-share settlement of a cashless option exercise, of which 14,037 shares were surrendered to us.
In July 2025, we issued 33,892 shares of common stock as part of restricted stock vesting, of which 12,126 shares were surrendered to us in satisfaction of related tax obligations. In August 2025, we issued 80,537 shares of common stock as part of restricted stock vesting, of which 28,515 shares were surrendered to us. In September 2025, we issued 51,012 shares of common stock as part of restricted stock vesting, of which 17,387 shares were surrendered to us.
(2) We paid $8.2 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises and vesting of restricted stock.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
Not applicable.

ITEM 4.  MINE SAFETY DISCLOSURES
Not applicable.
42

ITEM 5.  OTHER INFORMATION
Insider Trading Arrangements
During the three months ended September 30, 2025, no directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted , terminated , or modified any contract, instruction or written plan for the purchase or sales of our securities intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.

43

ITEM 6.  EXHIBITS
Exhibit
Number   Description of Document
3.1   Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 24, 2023).

3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on December 11, 2023).

31.1   Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.

31.2   Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant.

32.1   18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.

32.2   18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant.

101   The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 2024, (ii) Unaudited Condensed Consolidated Statements of Income for the three and nine month periods ended September 30, 2025 and 2024, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three and nine month periods ended September 30, 2025 and 2024, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2025 and 2024, (v) Unaudited Condensed Consolidated Statement of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements.

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

44

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  CORCEPT THERAPEUTICS INCORPORATED
   
Date: November 4, 2025 /s/ Joseph K. Belanoff
  Joseph K. Belanoff, M.D.
Chief Executive Officer
   
Date:
November 4, 2025 /s/Atabak Mokari
  Atabak Mokari
  Chief Financial Officer

Date: November 4, 2025 /s/Joseph D. Lyon
Joseph D. Lyon
Chief Accounting & Technology Officer

45